{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056876","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.585835+00:00","generated_at":"2026-06-02T08:18:25.338037+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Achieve Life Sciences reports Q1 net loss of $6.5M; cash $66.4M; ORCA-OL trial starts May 2024","bullets":["Cash, cash equivalents, restricted cash $66.4M as of March 31, 2024, after $60M upfront financing.","Net loss for Q1 2024 was $6.5M; total operating expenses $6.0M.","Feb 2024 financing raised $60M upfront with potential $64.2M from milestone-driven warrants.","ORCA-OL long-term safety trial on track to initiate enrollment in May 2024; NDA submission expected H1 2025.","Phase 2 ORCA-V1 vaping cessation results published in JAMA Internal Medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056876","json":"https://secwatch.observer/filing/0000950170-24-056876.json","markdown":"https://secwatch.observer/filing/0000950170-24-056876.md","text":"https://secwatch.observer/filing/0000950170-24-056876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017024056876/0000950170-24-056876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017024056876/achv-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:18:25.338037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f697b80d6fababb468cc405e912afd1a41fa52b","claim":"ACHIEVE LIFE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017024056876/0000950170-24-056876-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}